Roche's Chugai Licenses Innovative Antibody Technology To Accelerate Drug Discovery
This article was originally published in PharmAsia News
Executive Summary
Roche Japan unit Chugai Pharmaceutical Nov. 30 announced a licensing agreement with Tokyo-based new drug discovery firm Biocomber. Chugai will use Biocomber proprietary cell-free protein synthesis technology Puresystem to speed up global antibody drug development